The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 open-label study of conditionally active biologic ozuriftamab vedotin (BA3021) in failed PD-1/L1 treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
 
Alan Loh Ho
Stock and Other Ownership Interests - Rgenta
Honoraria - Endocrine Society; Physicans' Education Resource
Consulting or Advisory Role - AffyImmune Therapeutics; Ayala Pharmaceuticals; Cellestia Biotech; Eisai; Eisai; Elevar Therapeutics; Exelixis; ExpertConnect; InxMed; Kura Oncology; Merck; Prelude Therapeutics; Remix Therapeutics; Rgenta
Research Funding - Astellas Pharma; AstraZeneca; Ayala Pharmaceuticals; Bayer; Bayer; Bristol-Myers Squibb; Eisai; Elevar Therapeutics; Elevar Therapeutics; Genentech/Roche; Kura Oncology; Merck; Novartis
Patents, Royalties, Other Intellectual Property - LESIONAL DOSIMETRY METHODS FOR TAILORING TARGETED RADIOTHERAPY IN
 
Douglas Adkins
Consulting or Advisory Role - Boehringer Ingelheim; Calliditas Therapeutics; CUE Biopharma; Eisai Europe; Exelixis; Genmab/Seattle Genetics; Gilead Sciences; Immunitas; Jazz Pharmaceuticals; Kura Oncology; Merck; Seagen; TargImmune Therapeutics; Vaccinex
Research Funding - Adlai Nortye (Inst); AstraZeneca (Inst); BeiGene (Inst); BioAtla (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calliditas Therapeutics (Inst); Celgene (Inst); Cofactor Genomics (Inst); CUE Biopharma (Inst); Debiopharm Group (Inst); Epizyme (Inst); Genmab (Inst); Gilead Sciences (Inst); Hookipa Biotech (Inst); Immutep (Inst); ISA Pharmaceuticals (Inst); Kura Oncology (Inst); Lilly (Inst); Merck (Inst); NATCO Pharma (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst); Tizona Therapeutics, Inc. (Inst); Vaccinex (Inst)
 
Jochen H. Lorch
Consulting or Advisory Role - Bayer; Eisai; Genentech; Novartis
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Millennium (Inst); Novartis (Inst)
 
Jacob Stephen Thomas
No Relationships to Disclose
 
Jaspreet Singh Grewal
Honoraria - Curio Science; Eisai
Consulting or Advisory Role - Eisai
Speakers' Bureau - Bayer; BMS GmbH & Co. KG; Ipsen
Expert Testimony - Monsanto